Antisense oligonucleotides as a precision therapy for developmental and epileptic encephalopathies

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Developmental and epileptic encephalopathies (DEEs) are severe neurological disorders with early-onset seizures and developmental delays, often caused by genetic mutations.
• Current treatments for DEEs are primarily symptomatic, focusing on seizure management rather than addressing the root genetic cause.

Purpose of the Study:

• To review recent advancements in antisense oligonucleotide (ASO) technology for treating DEEs.
• To highlight the potential of ASOs as a targeted gene therapy approach for DEEs.

Main Methods:

• Review of preclinical and clinical studies on ASO applications in DEEs.
• Analysis of ASO efficacy in modulating gene expression and ameliorating disease phenotypes.

Main Results:

• ASOs demonstrate efficacy in vitro and in vivo for ameliorating DEE phenotypes.
• Ongoing clinical trials show promising outcomes for ASO-based therapies.

Conclusions:

• ASO technology represents a significant advancement in DEE treatment, offering targeted genetic intervention.
• The potential for precise, personalized medicine with ASOs could transform DEE therapy beyond symptomatic relief.